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C/EBPαscription factors, the E2 protein encoded by human papillomaviruses (HPV)
modulates the viral gene expression to support the life cycle of HPV, which depends on the differentiation of
the infected keratinocytes. The role of E2 as activator of viral transcription still remains unsolved.We showhere
that low amounts of E2 encoded by HPV16 efﬁciently activated the early promoter P97 of HPV16. In addition to
the long control region, this activation required high amounts of the cellular co-activator p300 and a novel
binding site for CCAAT enhancer-binding protein α (C/EBPα) located downstream of the P97 at position 480.
The expression of C/EBPα was shown previously to increase during keratinocyte differentiation. By
immunohistochemistry we demonstrate that the expression of p300 is induced in suprabasal epithelial cells
of HPV16 positive and negative squamous epithelium. Our data suggest that high levels of p300 and C/EBPα in
suprabasal layers of HPV16 positive cervical lesions allow the viral E2 protein to activate HPV16 early gene
expression.
© 2008 Elsevier Inc. All rights reserved.IntroductionInfection with high risk human papillomaviruses (HPV) belonging
to the Alpha-papillomaviruses is a prerequisite for the development of
cervical cancer. This is supported by the ﬁnding that in almost 100% of
cervical cancers, HPV DNA of genital high risk types such as HPV16 and
18 can be found (Munoz, 2000). While in benign lesions, the viral DNA
is maintained as an episome, its integration into the host genomewith
the loss of the E2 open reading frame is thought to be a crucial step in
malignant progression (Schwarz et al., 1985). By binding to four
binding sites located within the long control region (LCR), the E2
transcription factor can regulate viral transcription and replication
(reviewed in Longworth and Laimins, 2004). Reintroduction of E2 into
cervical cancer cell lines such as HeLa or SiHa, which harbor integrated
HPV18 and 16, respectively, results in sharp repression of E6 and E7
transcription by binding of E2 to the two promoter proximal binding
sites (Desaintes et al., 1997; Dowhanick et al., 1995; Goodwin and
DiMaio, 2000; Nishimura et al., 2000). The situation is different when
transiently transfected reporter constructs with the long control
region (LCR) including the early promoter were used. E2 was shown
to weakly activate (Bouvard et al., 1994; Steger and Corbach, 1997) or
weakly repress the early promoter (Soeda et al., 2006; Tan et al., 1992).
The speciﬁc effect may depend on the E2 expression level (Demeret
et al., 1997; Steger and Corbach, 1997). However with episomal,ger).
l rights reserved.replicating HPV16 DNA, no effect of E2 on HPV16 (16E2) transcription
could be observed. A close chromatin structure and methylation may
impede the binding of E2 to its sites (Bechtold et al., 2003; Kim et al.,
2003). These modiﬁcations were shown to change during differentia-
tion of the infected epithelium (Kalantari et al., 2008; Wooldridge and
Laimins, 2008).
The life cycle of HPV is linked to the differentiation program of the
infected keratinocytes. The activity of the HPV16 early promoter P97,
which slightly increases during keratinocyte differentiation, is con-
trolled by a combination of ubiquitous transcription factors such as
AP1, Oct1, TEF-1, YY1, and Sp1 binding to their sites within the LCR,
with a crucial role of AP1 (reviewed in Longworth and Laimins, 2004).
There is growing evidence that the C/EBP (CCAAT/enhancer-binding
protein) family of transcription factors, known to be involved in
differentiation of the keratinocytes (Smith et al., 2004), play a role in
regulating transcription in the HPV life cycle as well. The C/EBP family
is composed of at least six members, with C/EBPα, C/EBPβ, C/EBPδ and
C/EBPζ being expressed during keratinocyte differentiation in a
sequential manner. C/EBPα is found largely in suprabasal cell layers
(Maytin and Habener, 1998; Bull et al., 2002). Several C/EBP motifs
were identiﬁedwithin the HPV16 genome. The binding of C/EBPβ to its
recognition sequences within the LCR was shown to repress P97 (Kyo
et al., 1993) while two sites located within promoter 3′ sequences at
pos. 580–593 and 601–614 are supposed to mediate activation of the
late promoter at position 670 (P670) (Kukimoto et al., 2006). Moreover,
binding of C/EBPα to sequences within the late promoter of HPV16
increased upon keratinocyte differentiation (Carson and Khan, 2006).
Fig.1. E2 and p300 cooperate in activation of the early promoter P97 of HPV16. (A) Normal human primary epidermal keratinocytes (NHEK) were transfectedwith a luciferase reporter
construct containing HPV16 sequences from position 6150 to 885 in front of the luciferase gene (16LCR-E7-Luc). As shown in the schematic overview in (B), this fragment includes in
addition to P97, also P670. The four E2 binding sites are indicated. Five or 25 ng of an expression vector for 16E2 and 500 ng p300 vector were co-transfected. The basal activity of the
reporter construct was set as 1 and the fold activations were calculated. The standard deviations of four independent experiments are given. (B) The reporter constructs 16LCR-E7-Luc
and 16LCR-Luc, containing HPV16-speciﬁc sequences from position 7004 to 98, including P97, were co-transfected with 16E2 (5 and 10 ng) and p300 (500 ng) expression vectors into
RTS3b cells. The activity of each reporter construct in the presence of the empty vectors was set as 1 and the fold activations obtained by E2 and/or p300 were determined. The right
graph shows the relative luciferase activities (calculated by dividing the relative light units RLU by the protein concentration of the sample) of 16LCR-E7-Luc and 16LCR-Luc. (C) RNase
protection assays with RNA from CaSki or RTS3b cells, transfected either with 16LCR-E7-Luc or 16LCR-E7-p97mt-Luc, containing a mutation in the TATA box of P97, and with
expression vectors for 16E2 and p300, as indicated in the ﬁgure. As probe, radio-labeled c-RNA from position 7796 to 277 of HPV16was used. Transcripts spliced at the splice donor at
position 226 should yield a product of 129 nucleotides and unspliced transcripts a fragment of 180 nucleotides, as depicted in the overview.
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153U. Krüppel et al. / Virology 377 (2008) 151–159The homologous cellular co-activators of transcription CBP (CREB
binding protein) and p300 (here named CBP/p300) are involved in
control of HPV gene expression as well. They serve as co-activators for
cellular transcription factors binding to the LCRof HPV, such asAP1 or C/
EBP, and the virally encodedE2 (Lee et al., 2000;Müller et al., 2002; Peng
et al., 2000). CBP/p300 participate in a broad spectrum of biological
activities including cell cycle regulation, differentiation and apoptosis.
Important for co-activator activity of CBP/p300 is their acetyl-transfer-
ase (AT)activity bywhich theycanaddanacetyl group to lysine-residues
of histones or other transcription factors (Kalkhoven, 2004).
Here we set up to analyze the consequence of the interaction of
16E2 with p300 on regulation of HPV16 gene expression. We ﬁnd that
low amounts of 16E2 and p300 cooperated in activation of HPV16
gene expression. This activation concerned the early promoter and
required high amounts of p300, the LCR as well as the binding of C/
EBPα to a novel binding site at position 480. We demonstrate that the
expression of p300 is increased in the suprabasal layers of HPV16
positive cervical lesions. Our results suggest that a differentiation-
dependent increase in the expression of p300 and C/EBPαmay enable
E2 to activate HPV16 transcription.
Results
16E2 and p300 cooperate in activation of the HPV16 P97 promoter
Previously, we observed that the little activation of the late
promoter of HPV8, a high risk Beta-papillomavirus infecting the skin,
by low amounts of 8E2was efﬁciently increasedwhen the levels of theFig. 2. p300 expression is high in the suprabasal layers of HPV16-positive cervical sections
positive CIN1-2 and CIN3 lesions and of normal cervix using either a monoclonal antibody
counter-stained by Mayers hematoxilin solution.cellular co-activator p300 were elevated, indicating that p300
expression is a rate-limiting step in activation by E2 (Müller et al.,
2002; Müller-Schiffmann et al., 2006).
Since the interaction with p300 seems to be conserved among E2
proteins of PV (Lee et al., 2000; Müller et al., 2002; Peng et al., 2000)
we tested a functional relevance of the direct interaction between
16E2 and p300 (Marcello et al., 2000, and data not shown) on gene
expression of HPV16 with an HPV16-speciﬁc reporter construct
16LCR-E7-Luc, containing in addition to the LCR also the sequences
up to nt. 885 including P670. We used normal human epidermal
keratinocytes (NHEK) in transient transfection assays. Low concentra-
tions (5ng) of 16E2 slightly activated luciferase activity up to 2-fold,
while with 25ng expression vector, 16E2 slightly repressed (0.71-fold),
in correlationwith previous observations (reviewed in Longworth and
Laimins, 2004). Over-expression of p300 stimulated HPV16 promoter
activity 5-fold. Co-expression of 16E2 and p300 maximally yielded a
12-fold activation. With the higher amount of 16E2, the cooperation
with p300 was lost. Thus, p300 and low level of 16E2 can cooperate in
activation of HPV16 gene expression.
Fig.1B shows that the cooperative activation by 16E2 and p300 also
takes place in RTS3b cells, an HPV-negative skin keratinocyte cell line
(Purdie et al., 1993) when using 16LCR-E7-Luc. However, neither a
signiﬁcant activation by 16E2 or p300, respectively, nor a cooperative
effect between both was observed with the reporter construct 16LCR-
Luc, encoding HPV16 regulatory sequences up to position 98. Thus,
signiﬁcant activation of HPV16 gene expression by 16E2 and p300
requires sequences 3′ to the early promoter. Compared to 16LCR-E7-
Luc, the basal activity of 16LCR-Luc was about 10-fold higher (Fig. 1B). Immunohistochemical staining of 5 μm-thick parafﬁn-embedded sections of HPV16-
directed against p300 or, as a negative control, IgG fraction from mouse. Sections were
154 U. Krüppel et al. / Virology 377 (2008) 151–159but the stimulation by p300 was reduced (4-fold stimulation with
16LCR-E7-Luc vs 2-fold with16LCR-Luc). Due to technical reasons, our
construct 16LCR-E7-Luc started at pos. 6150, while 16LCR-Luc startedat pos. 7004. Deletion of the sequences from pos. 6150 to 7003 within
the 16LCR-E7-Luc-construct did not affect activation obtained by 16E2
and p300 (data not shown).
Fig. 3. A binding site for C/EBPα, located at pos. 480, mediates cooperation between 16E2 and p300. (A) Luciferase reporter constructs containing the HPV16 LCR including sequences
downstream of P97 up to the positions indicated in the ﬁgure were transiently co-transfected into RTS3b cells together with expression vectors for 16E2 and p300. The activity (RLU/
protein concentration) of each reporter construct was set as 1 and fold activations by E2 and p300 were calculated, respectively. The values represent the means of 4 experiments and
the standard deviations are given. (B) Schematic representation of the segment from pos. 97 to 885 of HPV16 with known transcription factors binding sites. The binding sites for C/
EBP factors have been identiﬁed by (Carson and Khan, 2006; Kukimoto and Kanda, 2001; Kukimoto et al., 2006; Stünkel et al., 2000) and this work), that for hSkn1 by (Kukimoto and
Kanda, 2001), for cMyb by (Carson and Khan, 2006) and for CDP by (Stünkel et al., 2000). The numbers beneath the drawing represent the positions of the 3′ truncated HPV16
reporter constructs used in (A). The sequence around pos. 480 is enlarged with the consensus sequence for C/EBP and CDP boxed as well as the mutations, which were introduced to
eliminate binding of C/EBP factors. For the EMSA shown in the left panel, GST-C/EBPα (lanes 1, 3, and 6) and GST-C/EBPβ (lanes 2, 4, and 7) were either incubated with a radio-labeled
oligonucleotide encoding the HPV16 sequence from pos. 460 to 489 (lanes 1–4) or with a mutated oligonucleotide as shown above (lanes 5–7). In lanes 3 and 4, the reactions were
preincubated with an excess of non labeled wildtype oligo and analyzed on a non denaturing gel. On the right panel, the result of a CHIP-Assay, performed with extracts of SiHa cells
either in the presence (lane 8) of the absence of an anti-C/EBPα antibody (lane 9) is shown. Precipitated DNA fragments were ampliﬁed by PCR using primers speciﬁc for HPV16 (pos.
356 to 532) or for actin coding sequences (C) 16LCR-E7-Luc and 16LCR-E7-480mt-Luc, with point mutations preventing the binding of C/EBP to BS480, either in the absence (16LCR-
E7-480mt-Luc) or in the presence (16LCR-E7-p97mt-480mt-Luc) of mutations within the TATA box of P97 were transiently transfected with an expression vector for C/EBPα. In the
graph on the left, the relative luciferase activity (RLU) of each reporter constructs was determined. In the graph on the right, the activity of each reporter construct was set as 1 and the
fold activation obtained by C/EBPαwas calculated, respectively. (D) The reporter constructs 16LCR-E7-Luc and 16LCR-E7-480mt-Luc were co-transfected with expression vectors for
16E2 and p300. The fold activations by 16E2 and p300 were shown in the graph as well as the standard deviations.
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present in the reporter construct 16LCR-E7-Luc (Glahder et al., 2003;
Grassmann et al., 1996; Rosenstierne et al., 2003). In order to analyze,
which promoter is activated by 16E2 and p300, we performed RNase
protection assays (RPA) with RNA isolated from transiently transfected
RTS3b cells. As a probe to detect transcripts initiated from P97, we used
a c-RNA from position 7769 to 277 of HPV16. The majority of the RNA
expressed from P97 is spliced from a splice donor at position 226 to
alternative splice sites at position 409 or 526 (Baker and Calef, 1996). A
protected fragment of 129 nucleotides corresponds to the spliced form
while the unspliced RNA yields a product of 180 nucleotides. Both
fragments could be detected with RNA from CaSki cells, an HPV16-
positive cervical carcinoma cell line, which we used as a positive
control. No HPV16 speciﬁc signal was present when only the reporter
construct was transfected. Low amounts of 16E2 induced weak signals
corresponding to the spliced and unspliced P97-derived transcripts.
The intensity of the bands was stronger after over-expression of
p300, and was further enhanced, when 16E2 and p300 had been co-
expressed. No signals corresponding to these transcripts were
detected when using a reporter construct with a mutation of the
TATA Box of P97 (16LCR-E7-p97mt-Luc) (Fig. 1C). When performing
RPA with c-RNA probes covering the sequences around P670, neither
16E2 nor p300 induced a speciﬁc signal (data not shown). These
results demonstrate that 16E2 and p300 activate the early promoter of
HPV16.
The intracellular level of p300 is increased in the suprabasal layers of
HPV16-positive CIN
The protein expression pattern of high risk HPV types in low grade
CIN1 resembles that found in benign warts caused by other PV and
may represent productive infection. In the suprabasal layers of the
infected epithelium, E6 and E7 are expressed from P97 to induce cell
proliferation and allow genome maintenance (reviewed in Doorbar,
2006). E2 protein was detected in parafﬁn-embedded sections of
cervical tissue of grade CIN1 and CIN2. Its expression was conﬁned to
the superﬁcial layers of the epithelium and speciﬁcally to the
koilocytic nuclei, with little expression of the intermediate or basal
layers (Maitland et al., 1998; Stevenson et al., 2000). Our results shown
in Fig. 1 suggest that efﬁcient activation of P97 depends on low
amounts of E2, high concentrations of p300 and sequences down-
stream of the early promoter. In order to address whether such a
regulation may be feasible during the natural life cycle of HPV16, we
analyzed the expression of p300 in CIN. We performed immunohis-
tochemical staining to detect p300 expression in parafﬁn-embedded
sections of sixteen HPV16-positive cervical lesions of varying severity,
which were used in a previous study (Weissenborn et al., 2003) and
kindly provided by U. Wieland. The presence of HPV16 DNA within
these lesions, which were histologically diagnosed as CINs grade 1 to
3, was determined by PCR (Weissenborn et al., 2003). Four
representative examples are shown in Fig. 2. In general, while the
nuclei of only a few of the cells within the basal layer were stained by
the p300 antibody, most cells of the suprabasal layers were stained
intensely and the most differentiated layers revealed no detectable or
weak p300 expression. The number of layers with strongly positive
cells was increased in CIN3-lesions (Fig. 2). This expression pattern
seems to be similar in normal, HPV-negative cervix, although in
normal cervix, the most differentiated cells also express detectable
amounts of p300. Currently, we do not know whether this difference
reﬂects changes in expression pattern of p300 in HPV-positive cervical
lesion. To verify this, a greater number of samples from normal cervix
should be tested, which are currently not available. From these results
and previous observations made by (Maitland et al., 1998; Stevenson
et al., 2000), it seems likely that in cells within the intermediate layers,
low amounts of 16E2 and high concentrations of p300 may have the
chance to meet and confer activation of P97.Binding of C/EBP factors to a novel binding site at position 480 mediates
the cooperative activation between 16E2 and p300
In order to map the sequence elements downstream of P97 that
mediate cooperative activation by 16E2 and p300,we constructed a set
of consecutive deletion mutants starting from nt. 885. Fig. 3A reveals
that the 10-fold activation obtained by 16E2 and p300 with 16LCR-E7-
Luc (up to nt. 885) was reduced to 8-fold with 16LCR-641-Luc and
16LCR-523-Luc, containing HPV16 sequences up to pos. 641 and 523,
respectively, although with these reporter constructs considerable
variations were observed for unknown reasons. Deleting the
sequences downstream of pos. 469 (16LCR-469-Luc) decreased
activation by 16E2 and p300 to 5.8-fold. Another drop of activity was
observed after removing the sequences downstreamof nt. 394 (16LCR-
394-Luc; the basis for this was not further investigated here)(Fig. 3A).
Analyzing the 54bp located between nt. 469 and 523 by the MAT-
Inspector-program to identify putative binding sites for transcription
factors revealed a consensus sequence for the family of C/EBP
transcription factors from position 469–488 at the negative strand
with the sequence pos.488– 5′ TTATATTATGGAATCTTTG 3′ –pos.469
(see Fig. 3B, which was named BS480). The HPV16 sequence matching
the consensus C/EBP motif, which is 5′ RTTGCGYAAY 3′ (with R=A or
G/Y=C or T) (Kyo et al., 1993), is underlined. The gelshift experiment
shown in Fig. 3B revealed that bacterially expressed, GST fused C/EBPβ
was able to speciﬁcally bind to an oligonucleotide encoding this
sequence. GST-C/EBPα also induced a mobility shift of the oligonu-
cleotide, although it was less efﬁcient compared to C/EBPβ for
unknown reasons. No complex formation was observed when a
labeled oligonucleotide with mutations of the C/EBP consensus motif
was used (Fig. 3B). The binding of C/EBPα to BS 480 of HPV16 was
conﬁrmed by chromatin immunoprecipitation (ChIP). HPV16 positive
SiHa cells were cross linked with formaldehyde and lysed, followed by
precipitation of speciﬁc protein–DNA complexes with an antibody
directed against C/EBPα. A DNA fragment covering nt. 356 to 523 of
HPV16 was ampliﬁed by quantitative PCR. The agarose gel in Fig. 3B
revealed that this fragment was present in the precipitate obtained
with the C/EBPα antibody. Ampliﬁcation of actin encoding sequences
was not successful, which served as negative control. This result
indicates that C/EBPα is located around nt. 480 of HPV16, integrated
into the genome of SiHa cells, although we cannot certainly exclude
that the precipitation of this fragment reﬂects the binding of C/EBPα
to the previously identiﬁed binding sites for C/EBPβ at pos. 580–593
and 601–614 as well (Kukimoto et al., 2006).
The functional relevance of this C/EBP binding site in regulation of
HPV16 gene expression was analyzed by mutational analysis. The
mutation destroying binding of C/EBP factors (see Fig. 3B) slightly
increased the relative luciferase activity of 16LCR-E7-Luc. Mutations
eliminating the TATA box of P97 (16LCR-E7-p97mt-Luc) led to a drop of
the relative light units (RLUs) into background (RLU b 200), conﬁrming
the observationmade by the RPA experiment shown in Fig. 1C that the
promoter activity observedwith 16LCR-E7-Luc derived solely fromP97.
The simultaneous mutation of BS480 in the context, where P97 was
eliminated (16LCR-E7-p97mt-480mt-Luc) increased RLUs above 1000
(Fig. 3C). This implies that the binding of C/EBP factors to BS480
contributes to repression of another promoter present in the reporter
construct. In over-expression assays, C/EBPβ was hardly able to
activate transcription from 16LCR-E7-Luc, independently of the
amount of expression vector transfected (data not shown). C/EBPβ
was suggested to repress the early promoter of HPV16 and to activate
the late promoter (Kukimoto et al., 2006). Our net result may reﬂect
these antagonizing activities. The over-expression of C/EBPα induced a
7.2 fold activation with 16LCR-E7-Luc. This activation was reduced to
4.8 fold due to themutationof the newbinding site at pos. 480 (Fig. 3C).
Presumably, this residual activation is mediated by binding of C/EBPα
to the series of binding sites for C/EBP, present within the LCR and/or
the region downstream of the early promoter (Kukimoto et al., 2006;
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effect of over-expressed C/EBPα. However, the co-expression of C/
EBPα with 16LCR-E7-Luc-p97mt-BS480mt-Luc increased RLUs up to
2000 (Fig. 3C). These results conﬁrm that the binding of C/EBPα to
BS480 contributes to the activation of P97, and to the repression of
another not yet identiﬁed promoter.
C/EBPα uses p300 as co-activator (Mink et al., 1997; Schwartz et al.,
2003). Moreover, p300 was suggested to mediate cooperation
between transactivators interacting with different domains of p300
(Mink et al., 1997). Thus we tested whether C/EBPα bound to its site at
pos. 480 is involved in the cooperation between E2 and p300.
Transient transfections revealed that the mutation of BS480 in the
context of 16LCR-E7-Luc reduced activation by E2 and p300 from
7 fold to 3.5 fold, while single activations obtained by E2 and p300 on
its ownwere hardly affected by the mutation (Fig. 3D), indicating that
binding of C/EBP factors to this site within HPV16 supports coopera-
tion between E2 and p300.
Discussion
Although the composition of the regulatory regions and the
regulation of gene expression between Beta-papillomaviruses and Al-
pha-papillomaviruses are completely different, some aspects are con-
served, for instance the interaction between the viral E2 protein and
p300. Previously we could show that the E2 protein of high risk
cutaneous HPV8 efﬁciently cooperates with p300 in activation of the
HPV8 late promoter (Müller et al., 2002). Our results presented here
reveal that the situation is fundamentally different in HPV16. Although
E2 and p300 cooperate in activation of HPV16 gene expression as well,
here the early promoter is concerned. The speciﬁc promoter targeting of
E2 and p300 in HPV8 and HPV16 obviously correlateswith the different
availability of p300 in the tissues infected by these viruses. While we
found previously that p300 is highly expressed in the most differ-
entiated layers in normal skin (Müller et al., 2002), immunohistochem-
istry shown here revealed that in mucosa of cervical dysplasias the
levels of p300 are elevated in the suprabasal layers. The zone of cells
expressing high amounts of p300 seems to increase during progression
from CIN1 to CIN3. In low grade lesions, which contain episomal HPV16
DNA, high amounts of p300 in the suprabasal layersmay allow the viral
E2 protein to activate P97. In high grade CINs, which usually do not
express E2, increased p300 co-activator level may have other functions,
for instance to support cellular proliferation. In line with this model is
our observation that cervical cancer cell lines such as CaSki and SiHa
express higher levels of p300 compared to NHEK and RTS3b cells (data
not shown). In correlation, the effect of over-expression of p300 in
cervical cancer cell lines is reduced (data not shown). Thus, RTS3B and
NHEK, the cells we used in this study, may reﬂect the situation in the
basal cell layers regarding p300 expression and allow us to study the
effect of increasing p300 concentrations. This set up seems to be valid,
since we can demonstrate that p300 is markedly induced in suprabasal
epithelial cells in bothviruspositive andnegative squamous epithelium.
Activation by 16E2 andp300depends on the bindingof E2 to its sites
(U.K. andG.S., datanot shown) andon the sequencesdownstreamofP97.
It is becoming more and more evident that the P97 downstream
segment of HPV16 not only plays a role in regulation of P670, but also in
modulating P97 activity. In our hands, these sequences conferred an
about 8-fold repression of P97. Previously, an inhibitory effect was
suggested to rely on the binding of CDP/cut (CCAAT-displacement
protein/cut homeodomain) to ﬁve binding sites (Stünkel et al., 2000).
CDP/cut associates with histone-deacetylase HDAC1 and thus directs
the deacetylation of histone tails, which results in a more closed
chromatin structure and impedes the access of transcription factors to
the DNA (reviewed in Bernard, 2000; Nepveu, 2001). In vivo, CDP/cut is
expressed at high levels in undifferentiated keratinocytes and expres-
sion decreases upon differentiation (Ai et al., 1999). Our results support
the followingmodel: in the suprabasal layers p300 might contribute torelieve repression by CDP/cut via the histone AT-activity of p300. In line
with this, the acetylation state of histone H3 and H4 located around
both promoter regions was shown to increase during keratinocyte
differentiation in the case of HPV31 (Wooldridge and Laimins, 2008).
Moreover, in response to differentiation, methylation of episomal
HPV16 DNA was lost (Kalantari et al., 2008). These modiﬁcations may
confer access of E2, expressed in some of the superﬁcial cells (Maitland
et al., 1998; Stevenson et al., 2000) to its sites within the episomal
HPV16 genome and allow it to activate. Another prerequisite for
cooperation with p300 is the binding of C/EBPα, expressed in
suprabasal skin layers as well (Maytin and Habener, 1998) to the
novel binding site at pos. 480. It seems possible that C/EBPα, directly
interacting with p300 as well (Schwartz et al., 2003) assists E2-
mediated recruitment of p300 to the P97 region. On the other hand, it
has been shown that C/EBPα (and also β) triggers phosphorylation of
the C-terminal part of p300, resulting in increased stability and
enhanced co-activator function (Schwartz et al., 2003). It is conceivable
that this C/EBP-induced modiﬁcation of p300 is a prerequisite for E2 to
increase transcription. Moreover, we have observed previously that E2
directly interacts with C/EBPα (Hadaschik et al., 2003). Via this
interaction E2 may be recruited to the promoter downstream segment
of HPV16, which may be a prerequisite for cooperation with p300.
In addition to its contribution to activation of P97, the binding of C/
EBPα to the site at pos. 480 seems to repress another promoter. A CDP/
Cutmotif at the coding strand overlapswith the newly identiﬁed C/EBP
BS (Stünkel et al., 2000). CDP/Cut is known to bind toAT-rich sequences
normally including the sequence 5′-TAAT-3′. Our mutation destroying
binding of C/EBPα leaves the CDP/Cut binding site intact (see Fig. 3B).
Thus, increased promoter activities as consequence of the mutation of
the BS480 should be due to loss of binding of C/EBPα and not to altered
binding of CDP/Cut. Repression of transcription by C/EBP factors may
occur via dimerization of the full length protein with an N-terminally
truncated version, p30, lacking the activation domain. Moreover, by
recruiting the co-repressor CA150, C/EBPα may be able to selectively
repress certain promoters (McFie et al., 2006). Which promoter in
HPV16 is repressed by C/EBPα? The C/EBP binding site 480 overlaps
with the 5′ end of transcripts (Grassmann et al., 1996). Thus, bound C/
EBPαmight interferewith the assembly of the preinitiation complex at
the corresponding promoter. However, these transcripts are upregu-
lated during differentiation (Grassmann et al., 1996). Upon keratino-
cyte differentiation increased binding of C/EBPα to the late promoter
regions of HPV16 and HPV31 has been described (Carson and Khan,
2006), making it unlikely that the promoter directing the transcripts
initiating at pos. 480 or P670 are negatively controlled by C/EBPα. The
P542 was suggested to be down regulated in differentiated epithelial
cells (Glahder et al., 2003; Rosenstierne et al., 2003). C/EBP may be
implicated in the control of this promoter.
Taken together our results suggest that the differentiation-
dependent increase of the concentration of the cellular factors p300
and C/EBPαmay enable 16E2 to activate HPV16 gene expression in the
suprabasal layers of in the infected epithelium.
Materials and methods
Plasmids constructs
The expression vector for p300 was described in (Eckner et al.,
1994), that for 16E2 and the reporter construct 16LCR-Luc in (Verres
et al., 1999). The reporter construct 16LCR-E7-Luc was obtained by
cloning a BamH1–Kpn1 fragment (from nt 6150 to 885) into the vector
pALuc (Dong et al., 1994). The deletion or point mutations were
introduced by cloning appropriate PCR products or by site directed in
vitromutagenesis. The pcDNA3.1 based expression for C/EBPα, vectors
for GST-C/EBPα and GST-C/EBPβ were described in (Hadaschik et al.,
2003). To obtain a probe for RPA, a HPV16 fragment from nucleotide
7749–277 was cloned into the vector pGEM4Z (Promega).
158 U. Krüppel et al. / Virology 377 (2008) 151–159Cell culture and transient transfections
The skin keratinocyte cell line RTS3b (Purdie et al., 1993) was culti-
vated in E-medium. Primary normal human epidermal keratinocytes
(NHEK)werepurchased fromCambrex and cultivated inKGM2medium.
Transient transfections of RTS3b cells and NHEK, using the FuGene
reagent (Roche Diagnostics), and the assaying of the luciferase activity
were described previously (Müller et al., 2002;Müller-Schiffmann et al.,
2006).
Protein expression, RNase protection assays and immunohistochemical
staining
Protein expression and RNase protection assays were performed as
described previously (Müller-Schiffmann et al., 2006). Parafﬁn
embedded sections of HPV16-positive cervical specimens, used in the
study from (Weissenborn et al., 2003) were stained with an antibody
directed against p300 (Calbiochem) as described in (Müller et al., 2002).
CHIP-Assay
The CHIP-Assay was performed according to the protocol of the
Chromatin-Immunoprecipitation kit from Upstate. Brieﬂy, cells were
treatedwith formaldehyde prior harvesting and sonicated to share the
chromatin solution to 300–500 bp DNA length. An antibody against C/
EBPα (14AA, Santa Cruz) was added to an aliquot of precleared lysate
and incubated over night. ProteinG-sepharosebeadswere addedand the
mixture was incubated for 2 h. After reversing the cross links, DNA was
isolated and used for PCR reaction with the fast start DNA master
SybrI green kit and a light cycler (Roche diagnostics). Finally, PCRs
were repeatedwith26cycles and fragmentswere loaded toanagarosegel.
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